Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript
12:11pm, Thursday, 01'st Aug 2024
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates
08:45am, Thursday, 01'st Aug 2024
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1.51 per share a year ago.
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
06:31am, Thursday, 01'st Aug 2024
– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 –
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
06:30am, Thursday, 01'st Aug 2024
– ACTIVATE-KidsT is Agios' First Pediatric Data Readout; Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adults with PK Deficiency Who are Regularly Transfused –
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:08am, Thursday, 25'th Jul 2024
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
07:00am, Thursday, 18'th Jul 2024
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announce
Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?
05:25am, Monday, 24'th Jun 2024
Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near
Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
07:41am, Wednesday, 12'th Jun 2024
Agios Pharmaceuticals develops therapies for rare diseases with a focus on Pyruvate Kinase activators like Pyrukynd for PK deficiency. AGIO is advancing its pipeline with research on Mitapivat for tha
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
01:45pm, Tuesday, 04'th Jun 2024
Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.
Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study
06:42am, Monday, 03'rd Jun 2024
Agios Pharmaceuticals said on Monday its experimental treatment for an inherited blood disorder met the main goal in a late-stage study.
– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo –
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
04:05pm, Thursday, 30'th May 2024
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
01:36pm, Wednesday, 29'th May 2024
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.
How Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43%
10:56am, Friday, 24'th May 2024
The mean of analysts' price targets for Agios Pharmaceuticals (AGIO) points to a 26.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session –
